Heiner Wedemeyer, MD
Interim results from a new phase 3 trial support the safety and efficacy of monotherapy with bulevirtide (Hepcludex, Gilead Sciences) in patients with chronic infection with the hepatitis delta virus.
The international, multicenter investigation concluded that 24 weeks of treatment with the first-in-class entry inhibitor was associated with significant decreases in viral RNA, and improvements in biochemical disease activity. The researchers said the findings affirm the August